[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.189.139. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 697
Citations 0
Comment & Response
June 7, 2016

Treatment for Patients With Newly Diagnosed Glioblastoma

Author Affiliations
  • 1University of Washington, Seattle
JAMA. 2016;315(21):2348. doi:10.1001/jama.2016.1844

To the Editor Dr Stupp and colleagues1 reported on the combined use of temozolomide and tumor-treating fields (TTFields) compared with temozolomide alone as adjuvant therapy in patients with newly diagnosed glioblastoma. The study of 315 patients demonstrated improvement in progression-free survival (3.1 months) and overall survival (4.9 months) in the TTFields-treated cohort (210 patients). The question is whether this study, an interim analysis of the total study population of 695 patients, is sufficiently compelling to change current therapies for glioblastoma.

First Page Preview View Large
First page PDF preview
First page PDF preview
×